Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Catumaxomab |
Synonyms | |
Therapy Description |
Catumaxomab is a trifunctional bispecific antibody that binds to Epcam and Cd3, and will bind to accessory immune cells such as macrophages, dendritic cells and natural killer cells, which redirects cytotoxic T-lymphocytes against tumor cells expressing Epcam, potentially inducing lysis of Epcam-expressing tumor cells (PMID: 32438548, PMID: 21188120). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Catumaxomab | Removab | Catumaxomab is a trifunctional bispecific antibody that binds to Epcam and Cd3, and will bind to accessory immune cells such as macrophages, dendritic cells and natural killer cells, which redirects cytotoxic T-lymphocytes against tumor cells expressing Epcam, potentially inducing lysis of Epcam-expressing tumor cells (PMID: 32438548, PMID: 21188120). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04819399 | Phase I | Catumaxomab | Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | Unknown status | DEU | 0 |